Therapeutical effect of modified adamantane copolymer compounds: study of molecular mechanisms.

S Rybalko; N Nesterova; S Diadiun; G Danylenko; V Danylenko; S Guzhova; Y Maksimov; V Arkadiev; N Ivans'ka; O Maksymenok; N Vrnycianu; E Zhtrebtsova; T Grygoreva

doi:10.18388/abp.2001_5132

Therapeutical effect of modified adamantane copolymer compounds: study of molecular mechanisms.

S Rybalko Lev Gromashevski Institute of Epidemiology and Infectious Diseases, Health Ministry of Ukraine, Kyiv.;
N Nesterova
S Diadiun
G Danylenko
V Danylenko
S Guzhova
Y Maksimov
V Arkadiev
N Ivans'ka
O Maksymenok
N Vrnycianu
E Zhtrebtsova
T Grygoreva

DOI: https://doi.org/10.18388/abp.2001_5132

Abstract

Copolymers of N-polyvinylpyrrolidone-acrylic acid (AB-1) and adamantane derivatives are known to possess marked antiviral activity in in vitro and in ovo models. Among the constructed preparations of AB-1 modified by adamantane derivatives some, especially AB-4 (modified by deitiforin), were found to show more extended antiviral activity and to inhibit markedly virus reproduction in susceptible permissive cell cultures and chicken embryos. In AB-4 treated cells and allantoic sacs, virus titers (influenza virus, herpes virus, and HIV) and virus antigen concentration were decreased. On the other hand, herpes virus-specific thymidine kinase and of DNA-polymerases isolated from Escherichia coli, Plectonema boryanum, and herpes virus type 1 infected murine brain tissue retained their activity after incubation with AB-4 or AB-2. The compounds investigated, in view of their effect on virus reproduction, are thought to be prospective as antiviral agents.

Published

2001-03-31

Issue

Vol. 48 No. 1 (2001)

Section

Articles

Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.